Cart
sales@molnova.com
Home - Products - Angiogenesis - JAK - CHZ-868

CHZ-868

CAS No. 1895895-38-1

CHZ-868( CHZ 868 | CHZ868 )

Catalog No. M12978 CAS No. 1895895-38-1

A potent type II JAK2 inhibitor; inhibits the proliferation of SET2 JAK2 V617F cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 421 Get Quote
50MG 741 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    CHZ-868
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent type II JAK2 inhibitor; inhibits the proliferation of SET2 JAK2 V617F cells.
  • Description
    A potent type II JAK2 inhibitor; inhibits the proliferation of SET2 JAK2 V617F cells (GI50=59 nM); reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms; reduces mutant allele burden in vivo, shows significant efficacy in Jak2V617F-driven polycythemia vera; orally active.Blood Cancer Preclinical.
  • In Vitro
    CHZ868 potently inhibits constitutive JAK2 and STAT5 phosphorylation in JAK2V617F SET2 cells. CHZ868 potently inhibits the proliferation of SET2 cells (GI50=59nM), and has 6-fold less growth inhibitory activity against CMK cells (GI50=378nM). At 100 nM CHZ868 has activity against 26 kinases, including JAK2 and TYK2. CHZ868 is thought to engage with the hinge region of JAK2 through two H-bonds, formed between the amino-pyridine of CHZ868 and the backbone-NH/CO of L932, while the pyridine is occupying the adenine pocket of the ATP binding site. CHZ868 potently suppresses the growth of CRLF2-rearranged human B-ALL cells, abrogates JAK2 signaling.
  • In Vivo
    CHZ868 is characterized by high passive permeability, good metabolic stability, and low water solubility, as well as by moderate blood clearance and good oral bioavailability, making it suitable for in vivo use. CHZ868 improves survival in mice with human or murine B-ALL. CHZ868 and dexamethasone synergistically induces apoptosis in JAK2-dependent B-ALLs and further improves survival compared to CHZ868 alone.
  • Synonyms
    CHZ 868 | CHZ868
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK
  • Research Area
    Cancer
  • Indication
    Blood cancer

Chemical Information

  • CAS Number
    1895895-38-1
  • Formula Weight
    423.4154
  • Molecular Formula
    C22H19F2N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 150 mg/mL
  • SMILES
    CC(NC1=NC=CC(OC2=CC=C3N(C)C(NC4=CC=C(F)C=C4F)=NC3=C2C)=C1)=O
  • Chemical Name
    Acetamide, N-[4-[[2-[(2,4-difluorophenyl)amino]-1,4-dimethyl-1H-benzimidazol-5-yl]oxy]-2-pyridinyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Meyer SC, et al. Cancer Cell. 2015 Jul 13;28(1):15-28. 2. Wu SC, et al. Cancer Cell. 2015 Jul 13;28(1):29-41.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • JAK3-IN-2

    A potent and highly selective JAK3 inhibitor with IC50 of 0.15 nM.

  • PF-06651600

    PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical

  • WDR5-0103 hydrochlor...

    WDR5-0103 is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM).

Sign In Join Free